Shawn C. Tomasello

Chief Executive Officer of the Issuer at CoRegen.

Aspen, CO
CoRegen

Raised on CoRegen filings

$96.9M

of $96.9M offered across 3 Form D filings

Form D filings: 3
Teammates: 13
Last filing: Feb 26, 2026

Company

Biotech · Aspen, CO

Cancer therapy that reprograms regulatory T cells

Cancer therapy that reprograms regulatory T cells

Investors: 7
Founded: 2022

Investors: 7
Sector: Biotech
Founded: 2022
HQ: Aspen, CO

CoRegen filings

CoRegen Form D filings
Filed	Security	Sold of offered	Filing
Feb 26, 2026	Equity	$13.5M/ $13.5M	Form D
May 22, 2025	Equity	$62.6M/ $62.6M	Form D
Feb 28, 2025	Equity	$20.8M/ $20.8M	Form D

EquityFiled Feb 26, 2026Form D
$13.5M/ $13.5M
EquityFiled May 22, 2025Form D
$62.6M/ $62.6M
EquityFiled Feb 28, 2025Form D
$20.8M/ $20.8M

Works with

Also named on CoRegen filings

John C. Thomas Jr.Chief Financial Officer of the Issuer, Form D signerForm D signer Sonja NelsonChief Financial Officer, Form D signerForm D signer Jonathan SimonsDirector Peter GelinasExecutive Officer Clifford C. Dasco, M.D.Chief Medical Officer of the Issuer David Lonard, PhDChief Science Officer of the Issuer Bert W. O'MalleyDirector Edward J. Benz, Jr.Director Lee FleisherDirector Sonal GuptaExecutive Officer Steve GorlinPresident and Vice Chairman of the Board Suneet VarmaDirector William Haseltine, PhD.Director